Sarepta Therapeutics Inc (SRPT) 13F Filing Data & Analysis (Q2 2026)

SRPT ranks #1891 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

SRPT is a disclosed holding of Two Sigma (Two Sigma Investments), one of the tracked superinvestors on AlphaSMO — it makes up 0.1% of that fund's own 13F portfolio.

334 institutions disclose a position in SRPT, but none treat it as a major bet — even 683 Capital Management, LLC, its most concentrated holder, allocates just 0.7% of its own portfolio to it.

Wealth Enhancement Advisory Services, LLC has trimmed its SRPT position for two straight quarters, cutting it by $1.5M while still holding $353.0K.

SRPT is down 3.9% today, but institutions show net buying of $217.2M this quarter — a divergence between today's price move and the underlying institutional flow.

SRPT reported a net loss of $136.7M over the trailing twelve months.

• Not yet profitable — net loss of $136.7M over the trailing twelve months
• Revenue declined 36.2% year over year
• Net income declined year over year, from -$58.0M to -$136.7M
• Operating cash flow was negative, using $205.5M in cash
• Current ratio of 2.32x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.94x equity — within a conventional range